Search results - Portal of Medical Data Models (MDM-Portal)

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 36 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Target Lesion Assessments; Confirmatory Response; Investigational Product Compliance - Pazopanib, 12-Lead ECG

- 5/22/19 - 1 form, 13 itemgroups, 188 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Liver Assessment,Local Laboratory - Thyroid Function,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Target Lesion Summary,Confirmatory Response - Response Summary,Confirmatory Response - New Lesions,Investigatoinal Product Compliance - Pazopanib,12-Lead ECG

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 30 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Local Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 5/22/19 - 1 form, 12 itemgroups, 182 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Liver Assessment,Local Laboratory - Thyroid Function ,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Investigatoinal Product Compliance - Pazopanib,Target Lesion Summary,Confirmatory Response - Response Summary,Confirmatory Response - New Lesions

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 24 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 5/22/19 - 1 form, 13 itemgroups, 188 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Liver Assessment,Local Laboratory - Thyroid Function,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Target Lesion Summary,Confirmatory Response - Response Summary,Confirmatory Response - New Lesions,Investigatoinal Product Compliance - Pazopanib,12-Lead ECG

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 18 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Local Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 5/21/19 - 1 form, 12 itemgroups, 182 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Liver Assessment,Local Laboratory - Thyroid Function ,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Investigatoinal Product Compliance - Pazopanib,Target Lesion Summary,Confirmatory Response - Response Summary,Confirmatory Response - New Lesions

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 12 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Laboratory - Thyroid Function Test; Urinalysis; Urinalysis - Local: 24h Protein Details; Target Lesion Assessments; Confirmatory Response; Investigational Product Compliance - Pazopanib, 12-Lead ECG

- 5/21/19 - 1 form, 13 itemgroups, 188 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Liver Assessment,Local Laboratory - Thyroid Function,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Target Lesion Summary,Confirmatory Response - Response Summary,Confirmatory Response - New Lesions,Investigatoinal Product Compliance - Pazopanib,12-Lead ECG

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 6 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Target Lesion Assessments; Confirmatory Response

- 5/21/19 - 1 form, 11 itemgroups, 166 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Liver Assessment,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Investigatoinal Product Compliance - Pazopanib,Target Lesion Summary,Confirmatory Response - Response Summary,Confirmatory Response - New Lesions

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 8 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry, Liver Events Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Biomarker Samples

- 5/17/19 - 1 form, 9 itemgroups, 158 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Liver Assessment,Investigatoinal Product Compliance - Pazopanib ,Biomarker Sample

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 4 - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry, Liver Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Biomarker Samples

- 5/17/19 - 1 form, 10 itemgroups, 164 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,12-Lead ECG,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Liver Assessment,Investigatoinal Product Compliance - Pazopanib ,Biomarker Sample

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 2 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry; Liver Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib

- 5/17/19 - 1 form, 8 itemgroups, 152 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Liver Assessment,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Investigatoinal Product Compliance - Pazopanib

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 1 - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry; Investigational Product Compliance - Pazopanib; Liver Events Assessment; Biomarker Samples

- 5/16/19 - 1 form, 8 itemgroups, 149 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,12-Lead ECG,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Investigational Product Compliance - Pazopanib,Liver Events Assessment,Biomarker Sample

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Screening - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry, Coagulation, Thyroid Function Test, Urinalysis; Urinalysis - Local: 24h Protein Details; Measurable/ Non-measurable Disease (Lesions)

- 5/16/19 - 1 form, 10 itemgroups, 187 items, 1 language

Itemgroups: Date of visit/ assessment,Vital Signs,12-Lead ECG,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Local Laboratory - Coagulation,Local Laboratory - Thyroid Function,Local Laboratory - Urinalysis,Urinalysis - Local: 24 hour Protein Details,Measurable/ Non-measurable Disease (Lesions)

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Relative Bioavailability of SB 497115-GR phase III tablets compared to SB-497115-GR phase II tablets 102863 - Medical Conditions

- 1/19/19 - 1 form, 2 itemgroups, 4 items, 1 language

Itemgroups: Administrative documentation,Disease

TEST StudyStudy ID: 102863 Clinical Study ID: 102863 Study Title: A randomized, open-label, two-period, period-balanced, crossover study with three parallel groups to evaluate the relative bioavailability of single oral doses of SB 497115-GR phase III tablets [50 mg, 75 mg, 100 mg] compared to SB-497115-GR phase II tablets [25 mg and 50 mg] in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Eltrombopag Trade Name: Eltrombopag Study Indication: Thrombocytopenia

Keywords

Table of contents

Selected data models

12 Search results.

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 1 - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry; Investigational Product Compliance - Pazopanib; Liver Events Assessment; Biomarker Samples

Relative Bioavailability of SB 497115-GR phase III tablets compared to SB-497115-GR phase II tablets 102863 - Medical Conditions

Keywords

Table of contents

Selected data models

12 Search results.

Contact

Help